Skip to main content
. 2020 Oct 16;58(2):221–229. doi: 10.1007/s00592-020-01610-9

Table 3.

The association of TMAO with DR in T2DM patients

Quartiles of plasma TMAO concentrations, µmol/L P-trend a Per-SD of ln (TMAO) P b
Q1 (< 0.346) Q2 (0.346–0.610) Q3 (0.610–1.0) Q4 (> 1.0)
N (DR/DWR) 14/16 12/19 22/9 24/6 72/50
OR (95% CI)
 Crude 1 (reference) 0.72 (0.26–1.99) 2.79 (0.97–8.03) 4.57 (1.45–14.40) 0.001 1.99 (1.29–3.07) 0.002
 Model 1 1 (reference) 0.87 (0.29–2.67) 5.21 (1.52–17.87) 9.62 (2.54–36.48)  < 0.001 2.64 (1.54–4.53)  < 0.001
 Model 2 1 (reference) 0.72 (0.22–2.37) 5.06 (1.39–18.46) 8.76 (2.21–34.76)  < 0.001 2.62 (1.51–4.55) 0.001
 Model 3 1 (reference) 0.73 (0.22–2.41) 4.60 (1.24–17.17) 7.42 (1.72–32.00) 0.002 2.31 (1.30–4.12) 0.005

TMAO, trimethylamine-N-oxide; T2DM, type 2 diabetes mellitus; DR, diabetic retinopathy; DWR, diabetes without diabetic retinopathy; BMI, body mass index; Q, quartile; SD, standard deviation; ln, logarithmic; OR, odds ratio; CI, confidence interval

aP values for linear trend across quartiles of TMAO were calculated by treating the median of each quartile as a continuous variable in binary logistic regression

bP values were obtained by binary logistic regression analyses. Model 1 was adjusted for age and gender. Model 2 was adjusted for age, gender, BMI, diabetes duration and hypertension. Model 3 was adjusted for covariates included in Model 2 plus estimated glomerular filtration rate